Is Everyone on GLP-1? Understanding the Surge in Popularity of GLP-1 Medications

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, and the perception that everyone is says more about how visible this drug class has become than about how many people take it. What is genuinely unusual is not the number of users but the speed at which the approved indication set expanded: in roughly three years these medications went from type 2 diabetes drugs to products carrying approvals across cardiovascular risk reduction, kidney outcomes, chronic weight management, obstructive sleep apnea and — under accelerated approval — liver fibrosis in noncirrhotic MASH. That regulatory expansion, not a social trend, is the substantive story worth understanding.

What Actually Expanded

The Ozempic label now carries three indications in adults with type 2 diabetes: glycemic control, reduction of major adverse cardiovascular events in those with established cardiovascular disease, and reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. Two of those are outcomes indications resting on dedicated trials.

The Wegovy label now covers weight reduction and long-term maintenance in adults and pediatric patients aged 12 and older, cardiovascular risk reduction, and noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval. Zepbound covers chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity.

New Dosage Forms Widened the Funnel

The category is no longer injection-only. Oral semaglutide exists as Rybelsus at 3, 7 and 14 mg and as Ozempic tablets at 1.5, 4 and 9 mg for type 2 diabetes indications. Wegovy tablets at 1.5, 4, 9 and 25 mg were approved in December 2025 for cardiovascular risk reduction and weight reduction in adults.

Foundayo (orforglipron), approved April 1, 2026 under NDA 220934, is an oral GLP-1 receptor agonist indicated for chronic weight management. Every additional dosage form removes a barrier for someone who would not have started otherwise, which is a more concrete explanation for growth than cultural momentum.

Higher Maintenance Options Arrived Too

The Wegovy label was revised in March 2026 to permit a maximum maintenance dosage of 7.2 mg once weekly for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. The supporting 72-week trial enrolled 1,407 patients with a mean baseline body weight of 113 kg and mean BMI of 39.9 kg/m².

That trial also reported that 5.4% of patients on 7.2 mg discontinued permanently because of adverse reactions versus 1% on placebo. Expanded options are not uniformly more tolerable options, and the labeling reflects that by conditioning access to the higher dosage on prior tolerance.

Why It Feels Universal

Visibility is not prevalence. A drug class discussed constantly in media, marketed directly to consumers, and visible in the physical appearance of people around you will feel far more widespread than usage figures support. Selection effects in your own social and online circles amplify that further.

The FDA has also issued warnings about direct-to-consumer marketing in this space, including warning letters to telehealth companies for marketing unapproved drugs such as retatrutide. Some of the sense of ubiquity is manufactured by exactly that marketing volume.

What the Surge Does Not Change

These remain prescription medications with a boxed warning regarding thyroid C-cell tumors observed in rodents, contraindications in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and warnings covering acute pancreatitis, acute gallbladder disease, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions and pulmonary aspiration during general anesthesia or deep sedation.

Popularity does not lower the threshold for a proper evaluation. In the pooled adult weight-reduction trials, adverse reactions led to permanent discontinuation in 6.8% of treated patients versus 3.2% on placebo. That is a meaningful minority for whom this class does not work out.

The Question Worth Asking

Not whether everyone is taking one, but whether you have a condition with a labeled indication and a prescriber who has evaluated you for it. That framing survives the trend cycle in a way that "should I get on this" does not.

PlexusDx protocols run through a clinical intake and a prescriber decision in all 50 states, dispensed from licensed 503A compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved finished products and are not reviewed by the FDA for safety, effectiveness or quality before marketing.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Why do GLP-1 medications seem so widespread?

Visibility rather than prevalence explains much of it. This class is discussed constantly in media, marketed directly to consumers, and its effects are physically visible, which makes it feel far more common than usage supports. Selection effects within personal and online circles amplify the impression. The FDA has also issued warning letters to telehealth companies marketing unapproved drugs in this space.

What actually drove the expansion of this drug class?

A rapid expansion of approved indications and dosage forms. Approvals now span glycemic control, major adverse cardiovascular event reduction, kidney outcomes, chronic weight management, moderate to severe obstructive sleep apnea in adults with obesity, and noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval. Oral products and higher maintenance dosages further widened access.

Are there oral options now?

Yes. Rybelsus at 3, 7 and 14 mg and Ozempic tablets at 1.5, 4 and 9 mg cover type 2 diabetes indications. Wegovy tablets at 1.5, 4, 9 and 25 mg were approved in December 2025 for cardiovascular risk reduction and weight reduction in adults. Foundayo (orforglipron), approved April 1, 2026 under NDA 220934, is an oral GLP-1 receptor agonist for chronic weight management.

Does wider use mean these are low-risk medications?

No. The labels carry a boxed warning regarding thyroid C-cell tumors observed in rodents, contraindications in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and warnings on pancreatitis, gallbladder disease, acute kidney injury from volume depletion and pulmonary aspiration under anesthesia. Discontinuation for adverse reactions occurred in 6.8% of treated adults versus 3.2% on placebo.

Is a higher dosage always better?

Not according to the labeling. The Wegovy label conditions access to the 7.2 mg maximum maintenance dosage on having tolerated 2.4 mg for at least four weeks and on additional weight reduction being clinically indicated. In the supporting 72-week trial of 1,407 patients, 5.4% on 7.2 mg discontinued permanently because of adverse reactions versus 1% on placebo.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.